Chitin Or Derivative Patents (Class 514/55)
-
Publication number: 20140024615Abstract: A product that includes a bioadhesive treatment solution for prevention of infectious diseases in the urinary tract of a female is provided. The product includes a polysaccharide. The product is positioned over the urinary tract of a female to act as a barrier against infectious transfer. A method for applying the product and a method for making the product are also disclosed.Type: ApplicationFiled: July 22, 2013Publication date: January 23, 2014Inventors: Allison London Brown, David Brown Robinson, Shantanu Gaur, Samuel Gideon Levy, Samuel Mack Hudson
-
Patent number: 8632565Abstract: Naphthalimide compounds are used in tissue bonding and protein cross-linking applications. When activated by an activating agent, such as light in the 400-500 nm absorption range, the naphthalimide compounds form chemically-reactive species that cross-link proteins, bond connective tissues together, and bond tissues and other biomaterials together. A naphthalimide-labeled biomolecule, such as a naphthalimide-labeled chitosan, is also capable of bonding tissues without subsequent direct illumination of the contacted tissue area. The naphthalimide compounds may be used in tissue or arterial repair, stabilization of an expanded arterial wall after angioplasty, tethering pharmaceutical agents to tissue surfaces to provide local drug delivery, and for chemically bonding skin care products, sunscreens, and cosmetics to the skin.Type: GrantFiled: February 21, 2013Date of Patent: January 21, 2014Assignee: Alumend, LLCInventors: Ronald E. Utecht, Kaia L. Kloster, Millard M. Judy, Kevin J. Vaska, James L. Matthews
-
Patent number: 8629122Abstract: The present invention provides a nucleus pulposus filler or the like which is to be packed into an area in deformed intervertebral disc wherein normal nucleus should be located and can be stabley maintained for a long time More preferably, the present invention provides a nucleus pulposus filler comprising a crosslinked chondroitin sulfate as an active ingredient. The photocrosslinked chondroitin sulfate is preferably the following one: a photocrosslinked chondroitin sulfate obtainable by freezing a photoreactive chondroitin sulfate-containing solution comprising: a photoreactive chondroitin sulfate to which a photoreactive group is bound; an aqueous solvent capable of dissolving the photoreactive chondroitin sulfate; and any one substance selected from the group consisting of an alcohol having aqueous solvent miscibility, a surfactant, and a cheleting agent; irradiating the resulting frozen product with light; and then melting the frozen product.Type: GrantFiled: April 22, 2011Date of Patent: January 14, 2014Assignee: Seikagaku CorporationInventors: Katsuya Takahashi, Tomoya Sato, Yukihiro Matsuyama
-
Patent number: 8629252Abstract: Non-crosslinked derivatives of oligo/polysaccharides of formula wherein: X is OH, O?M, NH—R1, O—R1; M is an alkaline or alkaline-earth metal, transition metal, or cation containing a quaternary nitrogen atom; Y is H or R2; R1: the residue of an oligo/polysaccharide; R2: the residue of a C1-C4 linear chain aliphatic carboxylic acid or citric acid; provided that at least one X is NH—R1 or O—R1, while the other two X are present in acid (OH) or salified form (OM).Type: GrantFiled: December 18, 2007Date of Patent: January 14, 2014Assignee: Sigea S.R.L.Inventors: Marco Bosco, Luca Stucchi, Fabrizio Picotti, Rita Gianni
-
Publication number: 20130345168Abstract: The present invention relates to a composition for preventing skin aging containing chitooligosaccharides as an active ingredient. The invention provides a cosmetic composition for preventing skin aging caused by UV rays containing chitooligosaccharides of 1-3 kDa, 3-5 kDa or 5-10 kDa molecular weight as an active ingredient.Type: ApplicationFiled: April 29, 2011Publication date: December 26, 2013Applicant: PUKYONG NATIONAL UNIVERSITY INDUSTRY UNIVERSITY COOPERATION FOUNDATIONInventors: Se-Kwon Kim, Chang-Suk Kong, Soon-Sun Bak, Jung-Ae Kim, Byul-Nim Ahn
-
Publication number: 20130336899Abstract: The invention discloses compositions and formulations for the treatment of clean or infected wounds, some of the inventive formulations can be used to reduce or eliminate microbial contamination from surfaces such as skin, and inanimate objects such as countertops, cooking utensils, medical devices, cookware, food, grooming aids and agricultural biocides, and the like. Some of these compositions and formulations are well suited for use in wound dressings. Some of the formulation can kill and/or inhibit the growth of pathogenic bacteria, fungi, spores and viruses. The formulations comprise a compound such as an osmoticum in high enough concentration to create an osmotic gradient and at least one compound that acts to comprise the integrity of a microorganism's membrane or cell wall. These formulations may optimally include at least one agent that thickens the formulations. In some aspects the formulation is in the form of an emulsion.Type: ApplicationFiled: October 11, 2011Publication date: December 19, 2013Applicant: Purdue Research FoundationInventors: Jianming Li, Sean Connell
-
Publication number: 20130330417Abstract: Nanocellulose foams containing at least one active ingredient and methods of preparing such nanocellulose foams containing one or more active ingredients are provided herein. In some embodiments, a method for preparing nanocellulose foam containing active ingredients may include forming a liquid mixture of nanocellulose, wherein the nanocellulose is at least one of dispersed, suspended or gelled in the liquid mixture; drying the liquid mixture of nanocellulose to form a nanocellulose foam; and mixing at least one active ingredient into at least one of the liquid mixture of nanocellulose or the nanocellulose foam. In some embodiments, a nanocellulose structure may include a nanocellulose foam comprising at least one of a carboxylate group, a hydroxyl group, or a sulfate group bonded to an active ingredient. In some embodiments, the nanocellulose structures are enhanced or crosslinked with metal cations.Type: ApplicationFiled: June 7, 2013Publication date: December 12, 2013Inventors: Hong Dong, James F. Snyder
-
Publication number: 20130330416Abstract: Technologies are described herein for styptic compounds comprising a hemostatic or styptic agent suspended within a hydrophobic carrier medium. Example carrier mediums may include waxes, lipids, oils, or combinations thereof. The compound may be a semisolid at room temperature and soft enough to be easily dispensed and formed into or onto bleeding tissue of an animal or human. The hydrophobic qualities of the carrier medium can protect the styptic agent from absorbing moisture. The carrier medium can mechanically support positioning treatments adjacent to the bleeding tissue. The carrier medium can further serve to mechanically seal the tissue to aid in hemostasis while also protecting the tissue from debris and contamination. The carrier medium can aid in maintaining moisture within the tissue. Slurry-based manufacturing processes can support a substantially homogeneous dispersal of styptic agent throughout the carrier medium.Type: ApplicationFiled: June 8, 2012Publication date: December 12, 2013Inventor: Robert J. Greenwald
-
Patent number: 8598143Abstract: The present invention relates to the discovery of a method for inhibiting RNA silencing in a target sequence-specific manner. RNA silencing requires a set of conserved cellular factors to suppress expression of gene-encoded polypeptide. The invention provides compositions for sequence-specific inactivation of the RISC component of the RNA silencing pathway, and methods of use thereof. The RISC inactivators of the present invention enable a variety of methods for identifying and characterizing miRNAs and siRNAs, RISC-associated factors, and agents capable of modulating RNA silencing. Therapeutic methods and compositions incorporating RISC inactivators and therapeutic agents identified through use of RISC inactivators are also featured.Type: GrantFiled: November 19, 2008Date of Patent: December 3, 2013Assignee: University of MassachusettsInventors: Gyorgy Hutvagner, Phillip D. Zamore
-
Publication number: 20130317416Abstract: The subject matter of the present invention is a sterile liquid composition dedicated to administration into or through the skin and/or the lips, wherein said composition comprises, in a physiologically acceptable medium, at least one photo-crosslinkable compound, wherein said compound comprises at least one activated photo-dimerizable group having at least one activated double bond and selected from photo-dimerizable groups carrying a stilbazolium function of formula (Ia) or (Ib) and wherein the photo-dimerizable groups carry a styrylazolium function of formula (II), the photo-dimerizable group(s) being carried by a partially or totally hydrolysed poly(vinyl acetate) polymer, a polysaccharide or a polyvinyl alcoholType: ApplicationFiled: December 20, 2011Publication date: November 28, 2013Applicant: L'OREALInventors: Henri Samain, Jean-Thierry Simonnet
-
Publication number: 20130302437Abstract: The present invention generally relates to new plant elicitor compositions, and the use of these compositions in agricultural applications, more particularly to protect plants against (infection by) plant pathogens and the corresponding methods of, and uses in, the protection of plants and crops by application of these compositions.Type: ApplicationFiled: January 24, 2012Publication date: November 14, 2013Inventors: Raffaele Buonatesta, Géraldine Van Aubel, Pierre Van Cutsem
-
Publication number: 20130303480Abstract: This disclosure relates generally to soft tissue augmentation threads, methods of making such threads and uses thereof, for example, in aesthetic applications (e.g., facial contouring, soft tissue augmentation products), surgery (e.g., sutures), drug delivery, negative pressure wound therapy, moist wound dressing, and the like.Type: ApplicationFiled: October 13, 2011Publication date: November 14, 2013Inventors: Kenneth N. Horne, Jayakumar Rajadas, Geoffrey C. Gurtner, Naveen Jayakumar
-
Publication number: 20130295151Abstract: The present invention relates to a process for the treatment of a cellulosic molded body, wherein the molded body is contacted with an acid solution of a chitosan. The process according to the invention is characterized in that the chitosan has a deacetylation degree of at least 80%, a nitrogen content of at least 7 w %, preferably at least 7.5 w %, a weight average molecular weight Mw (D) of 10 kDa to 1000 kDa, preferably 10 kDa to 160 kDa, and a viscosity in 1 w % solution in 1 w % acetic acid at 25° C. of 1000 mPas or less, preferably 400 mPas or less, in particular preferably 200 mPas or less.Type: ApplicationFiled: August 27, 2009Publication date: November 7, 2013Applicant: Lenzing AktiengesellschaftInventors: Sigrid Redlinger, Werner Richardt, Heinrich Firgo
-
Patent number: 8568803Abstract: The present invention relates to compositions for the modulation of inflammation in connective tissues in humans and animals and the modulation of markers of such inflammation, including COX-2, TNF-a, IL-1 (3, iNOS, p38, and chemokines, comprising any or all of anabolic, anti-catabolic, anti-oxidant and analgesic agents, including aminosugars, S-adenosylmethionine, arachadonic acid, GAGs, including pentosan, collagen type II, tetracyclines or tetracycline-like compounds, diacerin, super oxide dismutase, L-ergothioneine, methyl sulfanylmethane, one or more avocado/soybean unsaponifiables, and an analgesic, e.g., acetaminophen, and to methods of treating humans and animals by administration of these novel compositions to humans and animals in need thereof.Type: GrantFiled: August 7, 2009Date of Patent: October 29, 2013Assignee: Nutramax Laboratories, Inc.Inventors: Todd R. Henderson, Carmelita Frondoza
-
Publication number: 20130280303Abstract: A covering for delivering a therapeutic agent to a surgical site is provided. The covering may include a single or multi-compartment structure configured to at least partially retain the therapeutic agent until the covering is placed at a surgical site. Upon placement, the covering may facilitate transfer of the therapeutic agent to the surgical site. In some embodiments, the covering comprises an antimicrobial agent, a hemostatic agent, an anti-inflammatory agent, and/or a growth factor.Type: ApplicationFiled: April 19, 2012Publication date: October 24, 2013Applicant: Warsaw Orthopedic, Inc.Inventors: Susan J. Drapeau, Guobao Wei
-
Publication number: 20130266549Abstract: The present disclosure relates to a chitosan solution neutralized with amino-sugar carbonate buffering solution or amino-sugar phosphate buffering solution or phosphorylated aminosugar buffering solution. The resulting themogelling chitosan composition is highly biocompatible, isotonic and has the ability to rapidly turn into gel upon heating to the body temperature. It provides a novel chitosan-based composition to suitable for drug delivery, cell delivery and repair or regeneration of tissues and organs as well as other clinical treatment.Type: ApplicationFiled: June 3, 2013Publication date: October 10, 2013Inventors: Abdellatif CHENITE, Amine SELMANI
-
Patent number: 8552164Abstract: The invention relates to a novel method for production of nanofibrillar chitin, sustainable from an industrial manufacturing standpoint and suitable for producing chitin nanofibrils having improved properties and free from less crystalline components. The invention also relates to novel chitin nanofibrils obtained with said method and characterized by an increased dispersibility in aqueous media. The invention further relates to uses of nanofibrils in pastes and aqueous gels useful for topical on-skin application, to the manufacturing of materials of biomedical interest, as well as to the deposition of chitin nanofibrils on coating surfaces or the incorporation of the same inside of items like, e.g., fibers and fabrics of any Origin, natural as well as synthetic or mixed ones.Type: GrantFiled: November 23, 2006Date of Patent: October 8, 2013Assignee: Mavi Sud S.r.l.Inventors: Pierfrancesco Morganti, Corrado Muzzarelli
-
Publication number: 20130260993Abstract: The liquid elicitor of chitin and chitosan and micronutrient trace elements of the present invention involves induced systemic resistance (ISR)/innate immunity responses within plants. Dilute solutions are applied to propagules (fractions of microgram per seed and/or plant), which causes natural biotic defense responses by seedlings and/or plants. The application may be as seed coating, irrigation water, and/or foliar spray, wherein propagules bioactivate systemic disease defenses against bacteria, fungi, insects and parasitic nematodes. Benefits include enhanced biocontrol of seed viability, seed germination, seedling vigor, plant growth, flowering and harvest yields for legumes, grains, potatoes, vegetables, fruits, trees, sugar beet, and grass. By nature, this homeopathic invention benefits the entire environment by being natural, biodegradable, and by promoting beneficial soil organisms.Type: ApplicationFiled: March 28, 2012Publication date: October 3, 2013Inventors: James Linden, Richard J. Stoner, II
-
Patent number: 8546353Abstract: The present invention relates to a combination of a hyaluronan oligomer and/or polymer and a factor capable of mobilizing stem cells. The present invention also relates to a method for altering the relative amounts of blood cells and/or the types of blood cells in a subject by administering the combination to the subject. Further, the present invention relates to a method for mobilizing stem cells to the bloodstream of a subject by administering the combination to the subject. Additionally, the present invention relates to a hyaluronan oligomer and/or polymer.Type: GrantFiled: May 6, 2011Date of Patent: October 1, 2013Assignee: Glykos Finland OyInventors: Johanna Nystedt, Heidi Anderson, Tero Satomaa, Jari Natunen, Jari Helin, Juhani Saarinen
-
Publication number: 20130244972Abstract: A chitosan composition which forms a hydrogel at near physiological pH and 37° C., comprising at least one type of chitosan having a degree of acetylation in the range of from about 30% to about 60%, and at least one type of chitosan having a degree of deacetylation of at least about 70% is disclosed. Further disclosed is a chitosan composition which forms a hydrogel at near physiological pH and 37° C., that includes at least one type of chitosan having a degree of deacetylation of at least about 70% and a molecular weight of from 10-4000 kDa, and at least one type of a chitosan having a molecular weight of from 200-20000 Da. Further disclosed are methods of preparation and uses of the chitosan compositions.Type: ApplicationFiled: March 14, 2013Publication date: September 19, 2013Applicant: MOR RESEARCH APPLICATIONS LTD.Inventors: Noah Ben-Shalom, Zvi Nevo, Abraham Patchornik, Dror Robinson
-
Publication number: 20130244973Abstract: Combinations of therapeutic compounds for prophylaxis or treatment of hyperlipidemia and hyperlipidemia related disorders, such as hypercholesterolemia and the resultant atherosclerosis in a mammal. The combinations are useful for reducing serum cholesterol, and/or cholesteryl ester, triglycerides, phospholipids and fatty acids in a mammal. The methods of the preferred embodiments comprise administering to a mammal a first amount of polychitosamine and a second amount of an HMG-CoA reductase inhibitor (statin).Type: ApplicationFiled: May 3, 2013Publication date: September 19, 2013Applicant: Thorne Research, Inc.Inventors: Andrré Aubé, Jean-Guy Lehoux, Ryszard Brzezinski, Gilles Dupuis
-
Publication number: 20130244974Abstract: A composition suitable for use in wound healing, particularly for reducing post-surgical adhesions, containing cross-linked derivatives of chitosan and dextran polymers. A hydrogel forms when solutions of the polymers are combined.Type: ApplicationFiled: May 3, 2013Publication date: September 19, 2013Applicant: Medtronic Xomed, Inc.Inventors: Theodore Athanasiadis, Lyall Robert Hanton, Stephen Carl Moratti, Brian Harford Robinson, Simon Rae Robinson, Zheng Shi, James Simpson, Peter John Wormald
-
Patent number: 8536154Abstract: The present invention relates to a composition for activating mitochondria which contains a chitooligosaccharide as an active constituent. The chitooligosaccharide can increase the activity of mitochondrial enzymes and increase the amount of mitochondrial DNA, and thus it can be suitably used as an active constituent in the composition for activating mitochondria.Type: GrantFiled: November 27, 2009Date of Patent: September 17, 2013Assignee: Amorepacific CorporationInventors: Min Jeong Song, Eui Seok Shin, Si Young Cho, Jong Hee Sohn, Dae-Bang Seo, Wan Gi Kim
-
Publication number: 20130237498Abstract: This invention relates to the use of a biomaterial for the treatment, repair and/or enhancement of bodily tissue insufficiencies of the vocal chords, muscles, ligaments, cartilage, post-operative regions, sexual organs and/or weight supporting areas of the feet as well as other conditions of the bones and joints. The biomaterial for use in the invention may comprise an injectable bioresorbable polysaccharide composition wherein the polysaccharide may be succinochitosan glutamate. This invention also relates to the use of a biomaterial comprising an injectable bioresorbable polysaccharide composition in which resorbable particles may be in suspension, the said particles comprising or consisting essentially of chitin and/or chitosan, which may be free of any additional formulation modifying agents, and a process for manufacturing the same. The invention also includes the use of various medicaments in the biomaterial formulations to enhance the treatment of the affected area of the body.Type: ApplicationFiled: April 24, 2013Publication date: September 12, 2013Applicant: Cutanea Life Sciences, IncInventors: Robert J. Bitterman, Kimberley A. Forbes-McKean
-
Publication number: 20130230472Abstract: Naphthalimide compounds are used in tissue bonding and protein cross-linking applications. When activated by an activating agent, such as light in the 400-500 nm absorption range, the naphthalimide compounds form chemically-reactive species that cross-link proteins, bond connective tissues together, and bond tissues and other biomaterials together. A naphthalimide-labeled biomolecule, such as a naphthalimide-labeled chitosan, is also capable of bonding tissues without subsequent direct illumination of the contacted tissue area. The naphthalimide compounds may be used in tissue or arterial repair, stabilization of an expanded arterial wall after angioplasty, tethering pharmaceutical agents to tissue surfaces to provide local drug delivery, and for chemically bonding skin care products, sunscreens, and cosmetics to the skin.Type: ApplicationFiled: February 21, 2013Publication date: September 5, 2013Applicant: Alumend, LLCInventors: Ronald E. Utecht, Kaia L. Kloster, Millard M. Judy, Kevin J. Vaska, James L. Matthews
-
Patent number: 8524687Abstract: This invention relates to ophthalmic wound-healing pharmaceutical compositions based on amino acids and sodium hyaluronate.Type: GrantFiled: December 9, 2010Date of Patent: September 3, 2013Assignee: Professional Dietetics S.R.L.Inventors: Francesco Saverio Dioguardi, Edoardo Carlo Maria Conti, Federico Giovanni Maria Conti, Isabella Arborio Mella
-
Patent number: 8518379Abstract: The present invention provides medicaments useful for reducing phosphorus serum level, especially in those subjects affected from hyperphosphatemia. More specifically, the present invention relates to pharmaceutical compositions to be administered by oral route in fasting periods, in order to absorb phosphorus compounds from fluids of the enteric tract, especially from saliva.Type: GrantFiled: September 16, 2010Date of Patent: August 27, 2013Assignee: CM&D Pharma LimitedInventor: Vincenzo Savica
-
Patent number: 8518422Abstract: A cosmetic or dermatological preparation that is obtainable by combining collagen and/or a derivative thereof, chitosan and/or a derivative thereof and glycosylaminoglycan and/or a derivative thereof with one or more selected substances. This Abstract is not intended to define the invention disclosed in the specification, nor intended to limit the scope of the invention in any way.Type: GrantFiled: March 1, 2005Date of Patent: August 27, 2013Assignee: La Prairie Group AGInventors: Monika Mönks, Sybille Ibanez, Carmen Evangelisti, Sven Gohla
-
Patent number: 8513217Abstract: A tissue sealant for use in surgical and medical procedures for sealing the tissues of a living mammal is provided. The tissue sealant comprises a hydrogel which is formed by gelation of a premix disposed on the tissue to be sealed. The premix comprises alkylated chitosan or a gelatin, and a polybasic carboxylic acid or an oxidized polysaccharide, in an aqueous medium. The premix can also include a dehydrating reagent, a carboxyl activating reagent, or both. A specific use of the tissue sealant is in the repair of the dura mater after brain surgery to prevent leakage of cerebrospinal fluid. The tissue sealant may include a therapeutic or protective agent such as an antibiotic or an anti-inflammatory drug.Type: GrantFiled: September 15, 2010Date of Patent: August 20, 2013Assignee: Endomedix, Inc.Inventors: Weiliam Chen, John M. Abrahams
-
Patent number: 8507461Abstract: The present invention relates to compounds which are capable of exerting an inhibitory effect on the Na+ glucose cotransporter SGLT in order to hinder glucose and galactose absorption, as well as on lipase thus reducing dietary triglyceride metabolism, for use in the treatment of conditions which benefit therefrom (diabetes, Metabolic Syndrome, obesity, prevention of weight gain or aiding weight loss). These compounds comprise a non-absorbable, non-digestible polymer having a glucopyranosyl or galactopyranosyl or equivalent moiety stably and covalently linked thereto, said glucopyranosyl or galactopyranosyl moiety being able to occupy the glucose-binding pocket of a SGLT transporter.Type: GrantFiled: September 6, 2006Date of Patent: August 13, 2013Inventor: Abdalla Rifai
-
Publication number: 20130190227Abstract: Described herein are methods of inhibiting the growth of or killing a bacterium in an animal subject, preventing or delaying onset of an infection with a bacterium in an animal subject, preventing or delaying onset of a pathogen mediated disease or disorder in an animal subject, or reducing bacterial load in an animal subject, comprising administering an effective amount of a derivatized chitosan to the animal. Also described herein are preparations comprising a chitosan derivative for administration to an animal.Type: ApplicationFiled: March 12, 2013Publication date: July 25, 2013Applicant: SYNEDGEN, INC.Inventor: SYNEDGEN, INC.
-
Publication number: 20130164311Abstract: A composition of exceptionally dense chitosan and a novel method for producing the dense chitosan structure have been described. The novel production method employs coincident compression and vacuum on a neutralized chitosan polymer that results in an exceptionally dense chitosan film or membrane material. The dense chitosan film or membrane composition possesses multiple physical and clinically appealing qualities for a variety of medical applications on or in animals, mammals, or humans.Type: ApplicationFiled: December 22, 2011Publication date: June 27, 2013Applicant: Agenta Biotechnologies Inc.Inventors: Arthur A. DeCarlo, April Ellis, Thomas P. Dooley, Maria Belousova
-
Publication number: 20130165525Abstract: The invention relates to compositions and methods of treatment employing compositions comprising polyelectrolyte complexes. The compositions include a water-soluble first polyelectrolyte bearing a net cationic charge or capable of developing a net cationic charge and a water-soluble second polyelectrolyte bearing a net anionic charge or capable of developing a net anionic charge. The total polyelectrolyte concentration of the first solution is at least 110 millimolar. The composition is free of coacervates, precipitates, latex particles, synthetic block copolymers, silicone copolymers, cross-linked poly(acrylic) and cross-linked water-soluble polyelectrolyte. The composition may be a concentrate, to be diluted prior to use to treat a surface.Type: ApplicationFiled: February 21, 2013Publication date: June 27, 2013Applicant: The Clorox CompanyInventor: The Clorox Company
-
Publication number: 20130165970Abstract: Naphthalimide compounds are used in tissue bonding and protein cross-linking applications. When activated by an activating agent, such as light in the 400-500 nm absorption range, the naphthalimide compounds form chemically-reactive species that cross-link proteins, bond connective tissues together, and bond tissues and other biomaterials together. A naphthalimide-labeled biomolecule, such as a naphthalimide-labeled chitosan, is also capable of bonding tissues without subsequent direct illumination of the contacted tissue area. The naphthalimide compounds may be used in tissue or arterial repair, stabilization of an expanded arterial wall after angioplasty, tethering pharmaceutical agents to tissue surfaces to provide local drug delivery, and for chemically bonding skin care products, sunscreens, and cosmetics to the skin.Type: ApplicationFiled: February 21, 2013Publication date: June 27, 2013Applicant: Alumend, LLCInventors: Ronald E. Utecht, Kaia L. Kloster, Millard M. Judy, Kevin J. Vaska, James L. Matthews
-
Patent number: 8470369Abstract: Bone paste compositions are described, which promote bone healing and remodeling by stimulating bone marrow elements using a combination of hemopoietic agents, angiogenic agents and a bone molecular signaling material.Type: GrantFiled: March 10, 2009Date of Patent: June 25, 2013Assignee: Marfly 2, L.PInventor: J. Alexander Marchosky
-
Patent number: 8470998Abstract: The invention pertains to the use of an apoptosis inducing combination of at least a. a first expression modulating compound silencing the expression of at least a first target gene involved in apoptosis and b. a second expression modulating compound silencing the expression of at least a second target gene involved in apoptosis as a positive control in expression modulating assays. Also provided are suitable methods, kits and compositions.Type: GrantFiled: December 29, 2008Date of Patent: June 25, 2013Assignee: Qiagen GmbHInventors: Peter Hahn, Jörg Dennig, Wolfgang Bielke, Jie Kang
-
Patent number: 8466127Abstract: The present invention provides a PEGylated and fatty acid grafted chitosan oligosaccharide comprising a structural unit represented by the following Formula (I) and a structural unit represented by the following Formula (II) and synthesize method, wherein the chitosan oligosaccharide has a molecular weight of less than 200,000 Da, and a degree of deacetylation of 70%-100%, and part of free amino groups of chitosan oligosaccharide chain are replaced by a fatty acid or PEG, where n refers to degree of polymerization of the PEG, and R is an alkyl group having 11-21 carbon atoms. The grafting ratio of fatty acids is 1%-50%, and the grafting ratio of PEG is 0.05%-50%. The present invention also comprise a pharmaceutical composition comprising the PEGylated and fatty acid grafted chitosan oligosaccharide as a carrier, and use of the PEGylated and fatty acid grafted chitosan oligosaccharide in preparation of a pharmaceutical composition.Type: GrantFiled: June 16, 2009Date of Patent: June 18, 2013Assignee: Zhejiang UniversityInventors: Fuqiang Hu, Yongzhong Du, Hong Yuan, Pan Meng
-
Patent number: 8450296Abstract: This invention relates to the use of a biomaterial for the treatment, repair and/or enhancement of bodily tissue insufficiencies of the vocal chords, muscles, ligaments, cartilage, post-operative regions, sexual organs and/or weight supporting areas of the feet as well as other conditions of the bones and joints. The biomaterial for use in the invention may comprise an injectable bioresorbable polysaccharide composition wherein the polysaccharide may be succinochitosan glutamate. This invention also relates to the use of a biomaterial comprising an injectable bioresorbable polysaccharide composition in which resorbable particles may be in suspension, the said particles comprising or consisting essentially of chitin and/or chitosan, which may be free of any additional formulation modifying agents, and a process for manufacturing the same. The invention also includes the use of various medicaments in the biomaterial formulations to enhance the treatment of the affected area of the body.Type: GrantFiled: August 10, 2010Date of Patent: May 28, 2013Assignee: Cutanea Life Sciences, Inc.Inventors: Robert J. Bitterman, Kimberley A. Forbes-McKean
-
Publication number: 20130130898Abstract: The present invention relates to compositions of fungicidally active compounds comprising at least one active compound I selected from 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (3?,4?,5?-trifluoro-biphenyl-2-yl)-amide (fluxapyroxade), bixafen, fluopyram, isopyrazam, sedaxane, penflufen and penthiopyrad and at least one further active component II as defined below.Type: ApplicationFiled: August 2, 2011Publication date: May 23, 2013Inventors: Markus Gewehr, Jochen Dietz, Egon Haden
-
Patent number: 8445463Abstract: This invention relates to the use of a biomaterial for the treatment, repair and/or enhancement of bodily tissue insufficiencies of the vocal chords, muscles, ligaments, cartilage, post-operative regions, sexual organs and/or weight supporting areas of the feet as well as other conditions of the bones and joints. The biomaterial for use in the invention may comprise an injectable bioresorbable polysaccharide composition wherein the polysaccharide may be succinochitosan glutamate. This invention also relates to the use of a biomaterial comprising an injectable bioresorbable polysaccharide composition in which resorbable particles may be in suspension, the said particles comprising or consisting essentially of chitin and/or chitosan, which may be free of any additional formulation modifying agents, and a process for manufacturing the same. The invention also includes the use of various medicaments in the biomaterial formulations to enhance the treatment of the affected area of the body.Type: GrantFiled: August 10, 2010Date of Patent: May 21, 2013Assignee: Cutanea Life Sciences, Inc.Inventors: Robert J. Bitterman, Kimberley A. Forbes-McKean
-
Patent number: 8445465Abstract: The present invention relates to a glycol chitosane derivative, a preparation method thereof and a drug delivery system comprising the same. More specifically, the invention relates to a glycol chitosan derivative, which can form nano-sized self-assembled structures and has both temperature sensitivity and biodegradability so as to be suitable for use as a drug delivery system, as well as a preparation method thereof and a drug delivery system comprising the same.Type: GrantFiled: December 21, 2010Date of Patent: May 21, 2013Assignee: Chungnam National University Collaboration FoundationInventors: Kang Moo Huh, Zheng Zheng Li
-
Patent number: 8445464Abstract: This invention relates to the use of a biomaterial for the treatment, repair and/or enhancement of bodily tissue insufficiencies of the vocal chords, muscles, ligaments, cartilage, post-operative regions, sexual organs and/or weight supporting areas of the feet as well as other conditions of the bones and joints. The biomaterial for use in the invention may comprise an injectable bioresorbable polysaccharide composition wherein the polysaccharide may be succinochitosan glutamate. This invention also relates to the use of a biomaterial comprising an injectable bioresorbable polysaccharide composition in which resorbable particles may be in suspension, the said particles comprising or consisting essentially of chitin and/or chitosan, which may be free of any additional formulation modifying agents, and a process for manufacturing the same. The invention also includes the use of various medicaments in the biomaterial formulations to enhance the treatment of the affected area of the body.Type: GrantFiled: August 10, 2010Date of Patent: May 21, 2013Assignee: Cutanea Life Sciences, Inc.Inventors: Robert J. Bitterman, Kimberley A. Forbes-McKean
-
Publication number: 20130123213Abstract: A modified starch material for biocompatible hemostasis, biocompatible adhesion prevention, tissue healing promotion, absorbable surgical wound sealing and tissue bonding, when applied as a biocompatible modified starch to the tissue of animals. The modified starch material produces hemostasis, reduces bleeding of the wound, extravasation of blood and tissue exudation, preserves the wound surface or the wound in relative wetness or dryness, inhibits the growth of bacteria and inflammatory response, minimizes tissue inflammation, and relieves patient pain. Any excess modified starch not involved in hemostatic activity is readily dissolved and rinsed away through saline irrigation during operation. After treatment of surgical wounds, combat wounds, trauma and emergency wounds, the modified starch hemostatic material is rapidly absorbed by the body without the complications associated with gauze and bandage removal.Type: ApplicationFiled: January 11, 2013Publication date: May 16, 2013Inventor: Xin Ji
-
Publication number: 20130122063Abstract: A method of uncoupling mitochondria in a subject including administering nanotubes to the subject in a therapeutically effective amount, wherein the nanotubes are self-rectifying is provided. A method of decreasing reactive oxygen species and decreasing detrimental loading of Ca2+ into mitochondria is provided, including administering a pharmaceutically effective amount of nanotubes into the subject. A method of reducing weight, treating cancer, reducing the effects of traumatic brain injury, or reducing the effects of ageing, in a subject including administering a pharmaceutically effective amount of nanotubes into the subject is also provided.Type: ApplicationFiled: December 18, 2012Publication date: May 16, 2013Applicant: University of Kentucky Research FoundationInventor: University of Kentucky Research Foundation
-
Patent number: 8431119Abstract: The present invention relates to pharmaceutical compositions that act on the p53 protein or its gene and methods of use for the treatment of neurodegenerative diseases.Type: GrantFiled: August 22, 2007Date of Patent: April 30, 2013Assignee: Aventis Pharma S.A.Inventors: Jacques Mallet, Frederic Revah, Jean-Marie Stutzmann
-
Patent number: 8426384Abstract: This invention relates to wound-healing pharmaceutical compositions in the form of a sterile powder based on amino acids and sodium hyaluronate.Type: GrantFiled: December 9, 2010Date of Patent: April 23, 2013Assignee: Professional Dietetics S.r.l.Inventors: Francesco Saverio Dioguardi, Edoardo Carlo Maria Conti, Federico Giovanni Maria Conti, Isabella Arborio Mella
-
Publication number: 20130095087Abstract: An in situ gel-forming composition is disclosed. The in situ gel-forming composition comprises one or more absorbable polymers, solvents such as N-methyl-2-pyrrolidone, polyethylene glycol or DMSO, and optionally one or more bioactive agent. The composition forms a hydrogel or semi-solid mass on contact with an aqueous environment. The method of using in situ gel-forming composition for various applications is also disclosed.Type: ApplicationFiled: October 17, 2011Publication date: April 18, 2013Applicant: POLY-MED, INC.Inventors: Shalaby W. Shalaby, Joel Corbett, Jason Olbrich
-
Publication number: 20130096082Abstract: The invention discloses a hemostatic composition composing chitin or a water insoluble chitin derivative, especially water insoluble chitosan, in particulate form, wherein the composition is present in paste form.Type: ApplicationFiled: October 10, 2012Publication date: April 18, 2013Applicants: Baxter Healthcare S.A., Baxter International Inc.Inventors: Baxter International Inc., Baxter Healthcare S.A.
-
Publication number: 20130090306Abstract: The present invention pertains to chitosan beads consisting of chitosan cross-linked with citrate ions. The present invention furthermore pertains to a filler comprising such chitosan-citrate beads. In one embodiment of the instant invention the filler is a dermal filler. In one further embodiment of the present invention the dermal filler is for the treatment of wrinkles and/or folds. In another embodiment of the instant invention the filler is for use in the treatment of a medical condition. The filler provided in the present invention may further comprise one or more active pharmaceutical ingredients. Further, the present invention pertains to a process for preparing the filler as claimed herein.Type: ApplicationFiled: April 7, 2011Publication date: April 11, 2013Applicant: MERZ PHARMA GmbH & CO. KGaAInventors: Kevin Kiehm, Bernhard Hauptmeier, Peter Boderke
-
Patent number: 8415323Abstract: The present invention relates to reducing accumulation of viral genomes in a target cell. In particular the present invention provides compositions and methods for combating viral infection through RNA interference. Specifically the present invention provides cellular microRNA mimics for treating virus-infected subjects.Type: GrantFiled: August 27, 2008Date of Patent: April 9, 2013Assignee: The Regents of the University of CaliforniaInventor: Michael David